Research

Vaccine Shows Promise Against Pancreatic, Bowel Cancers

AUG 12 2025·Updated AUG 13 2025

Story

Image credit: Ed Us/Unsplash

The Facts

A phase 1 clinical trial of the ELI-002 2P vaccine involving 25 patients with pancreatic and colorectal cancers who had KRAS mutations and minimal residual disease after standard treatment has found evidence suggesting that the off-the-shelf vaccine can produce an immune response against the cancer.
guardian
NBC
The vaccine targets KRAS gene mutations, which occur in approximately 90% of pancreatic cancers and 40% of colorectal cancers, using peptides that train immune cells to recognize and attack mutated cancer cells.
Bioengineer.org
NBC
After a median follow-up of 19.7 months, 84% of patients generated KRAS-specific T-cell responses, with 68% developing strong immune responses above a predetermined threshold of a 9.17-fold increase over baseline.
Newswise
Nature
Patients with stronger immune responses had better outcomes, with the median remaining relapse-free during the study while those with weaker responses typically relapsed after 3.02 months. Similarly, the stronger responders also lived longer, with the median still alive by the end of the study, compared to an average survival of about 16 months for those with weaker responses.
Newswise
Nature
Unlike personalized cancer vaccines that require tumor sequencing for each patient, ELI-002 2P is an off-the-shelf vaccine that can be manufactured in bulk and administered more rapidly to patients with KRAS mutations.
EuroNews
Independent
The vaccine uses amphiphile technology to deliver antigens directly to lymph nodes where immune responses are activated, and 67% of tested patients developed immune responses to additional tumor mutations beyond those targeted by the vaccine.
Newswise
Nature

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Narrative A

This breakthrough represents a game-changer for pancreatic cancer patients who face dismal survival odds. The vaccine's ability to generate lasting immune responses without requiring personalized manufacturing makes it accessible and cost-effective. Results showing patients living cancer-free for extended periods offer genuine hope where few options existed before.

NBC

Cancer Today

Narrative B

While early results appear promising, this remains a small phase 1 trial with significant limitations that warrant caution. The study lacked controls, combined two different cancer types with varying prognoses, and requires validation in larger randomized trials before clinical benefit can be confirmed. Previous vaccine approaches have failed to translate into meaningful patient outcomes.

guardian

Medscape